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Background: The aim of this study was to investigate whether the maximum standardized uptake value (SUVmax)
measured on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)
could be used as the primary means of differential diagnosis of thyroid nodules when tumor volume is assessed.
Methods: We studied 192 patients who underwent preoperative 18F-FDG PET/CT followed by thyroidectomy. We
evaluated the correlation between the volume of thyroid nodules, 18F-FDG uptake on visual analysis, and the mean
SUVmax measured on 18F-FDG PET/CT.
Results: When stratified by tumor volume, the mean SUVmax was higher in malignant than in benign nodules in
nodules ≥1 cm3 (p < 0.001). However, it did not differ between benign and malignant nodules smaller than 1 cm3. At a
cut-off value of SUVmax of 6, the respective sensitivities of 18F-FDG PET/CT, ultrasonography, and fine needle aspiration
cytology were 60.8, 96.4, and 99.1 %, and the respective specificities were 95.9, 98.2, and 96.8 %.
Conclusions: 18F-FDG PET/CT is limited as a primary modality in the differential diagnosis of benign and malignant
thyroid nodules because of its low sensitivity.
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Unlike normal tissue, malignant tumors are character-
ized by increased glycolysis, which leads to elevated glu-
cose uptake. Fluorine-18 fluorodeoxyglucose positron
emission tomography/computed tomography (18F-FDG
PET/CT) makes use of this to aid the diagnosis and sta-
ging of various human malignancies.
In recent years, 18F-FDG PET/CT has become widely
used to diagnose thyroid cancer; it is especially useful in
identifying sites of recurrence in patients with elevated
serum thyroglobulin and negative whole body radio-
active iodine scans after thyroidectomy for differentiated
thyroid carcinoma [1–3]. 18F-FDG PET/CT also has po-
tential advantages in the detection of distant metastasis* Correspondence: kytae@hanyang.ac.kr
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effectiveness is not determined. However, the role of 18F-
FDG PET/CT in the differential diagnosis of benign and
malignant thyroid nodules is not yet well-established in
clinical practice because some benign thyroid nodules
show high 18F-FDG uptake, while some malignant nodules
are not visualized at all. Consequently, there is a paucity
of data regarding the role of 18F-FDG PET/CT in the dif-
ferential diagnosis of thyroid nodules; the few studies that
exist were conducted in small series of patients [4–6] or
in patients whose nodules were identified incidentally dur-
ing routine health checks [7–9]. In addition, while these
studies estimated the mean maximum standardized up-
take value (SUVmax) of 18F-FDG, they failed to consider
the effect of nodule size. Other studies have enrolled pa-
tients with metastatic thyroid cancer or those with diffuse
thyroid uptake of 18F-FDG.
Our aim in the present study was to establish whether
the SUVmax measured on 18F-FDG PET/CT could be ale distributed under the terms of the Creative Commons Attribution License
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malignant thyroid nodules according to tumor volume.Methods
Patients
We retrospectively studied 192 patients who underwent
thyroidectomy for thyroid nodules and received a pre-
operative 18F-FDG PET/CT scan out of about 3500 pa-
tients who were diagnosed with thyroid nodule in our
institute between January 2007 and December 2009. Of
the tumors, 152 were malignant and 40 benign. Among
the malignant cases, there were 146 papillary carcinomas,
3 follicular carcinomas, and 3 anaplastic carcinomas. The
benign cases comprised 38 nodular hyperplasias and 2 fol-
licular adenomas. Of the patients, 23 (15 %) were men
and 129 (85 %) women. The mean age was 56 years, and
all patients had normal thyroid function. The study proto-
col was approved by the Institutional Review Board of
Hanyang University Hospital.
In this study, 141 patients with malignant nodule under-
went 18F-FDG PET/CT scan to evaluate distant or re-
gional metastasis after diagnosis of thyroid cancer by fine
needle aspiration cytology (FNAC) according to the pa-
tient’s request or the recommendation of the doctors.
Thirty-two patients with incidentally found benign and
malignant nodule underwent 18F-FDG PET/CT scan for
the purpose of routine health examination or evaluation
of metastasis from other malignancy, and 19 patients of
study group underwent 18F-FDG PET/CT for research
purposes after submitting their written informed consent,
especially in patients with follicular neoplasm or indeter-
minate cases on FNAC.
Exclusion criteria were recurrent thyroid cancer, dif-
fuse 18F-FDG uptake by the thyroid that could not be
differentiated from thyroid nodule on 18F-FDG PET/CT,
and a history of thyroid surgery, or radiotherapy in the
head and neck region for other diseases.
Patients with benign nodules underwent thyroidec-
tomy: (1) for cosmetic purposes, (2) at their request, (3)
if malignancy was suspected on ultrasonography (US), or
(4) if their FNAC results were classified as inadequate or
indeterminate.
Thyroid US and ultrasound-guided FNAC were per-
formed by an experienced board-certified specialist in all
cases. The FNAC results were categorized as (1) inad-
equate, (2) benign, (3) indeterminate (e.g., follicular neo-
plasm or atypia), (4) suspected malignancy, or (5)
malignancy. In cases of microcalcification, irregular
margins, marked hupoechogenity, or a taller-than-wide
shape on US, the nodules were interpreted as malignant.
Nodule diameter on US was used to calculate nodule
volume. If there were multiple nodules on US, we mea-
sured a single nodule that was also examined by FNAC.18F-FDG PET/CT
Whole body PET/CT images were acquired using a ded-
icated PET/CT system (Biograph 6, Siemens Medical
Systems, Knoxville, TN, USA). Hard exercise was pro-
hibited for several days, and the patients fasted for at
least 6 h prior to the scan. Blood glucose levels were tested
to confirm they were below 200 mg/dL. After an intraven-
ous injection of 18F-FDG (0.21 mCi/kg), the patients were
asked to wait for 1 h in a dimly lit room and encouraged
to drink 1 L of water. A CT scan (80 mA and 140 kVp)
was performed to correct attenuation prior to the PET
scan. CT scanning was performed in 5-mm sections from
the base of the skull to the proximal thigh; the images
were reconstructed using a 512 × 512 matrix and a 50-cm
field of view. PET scans were obtained from the proximal
thigh to the base of the skull (six to seven bed positions,
2 min 30 s per each position), and the images were recon-
structed with a 168 × 168 matrix, using the ordered subset
expectation maximum iterative reconstruction algorithm,
a 5-mm Gaussian filter, and a 50-cm field of view.
18F-FDG uptake by thyroid nodules was evaluated by vis-
ual analysis using the naked eye and quantitative measure-
ment using SUVmax. If there is any focal increased uptake
lesion detected in anterior neck on maximum intensity
projection images by visual analysis, the uptake of thyroid
nodule was verified by thorough examination of the axial
PET/CT images by two nuclear medicine physicians. Then,
SUVmax was measured for each thyroid nodule using
volume of interest (VOI). SUV was calculated as follows:
SUV= [FDG activity concentration (Bq/mL)] × [total lean
body mass (kg)]/[injected FDG activity (Bq)].
Statistical analysis
Statistical analyses were carried out with SPSS 17.0
(SPSS Inc., Chicago, IL, USA). We compared the uptake
of 18F-FDG analyzed visually and SUVmax determined
on 18F-FDG PET/CT between malignant and benign thy-
roid nodules. The same comparisons were made when the
nodules were stratified by volume using a cut-off volume
of 1 cm3. An independent Student t-test was performed to
identify differences in SUVmax between the malignant and
benign thyroid nodules. Pearson’s correlation coefficients
were calculated to determine the correlation between nod-
ule volume and the SUVmax.
Results
Differences in volume and SUVmax between malignant
and benign nodules
The mean volumes of the malignant and benign nodules
were not significantly different (11.63 ± 7.27 mL vs.
10.98 ± 4.56 mL; p = 0.968). On the other hand, the mean
SUVmax was significantly higher in malignant than in be-
nign nodules (5.11 ± 0.49 vs. 2.32 ± 0.25; p < 0.001). Among
the malignant cases, the mean SUVmax was 4.80 ± 0.46 for
Table 1 18F-FDG uptake by visual analysis of 18F-FDG PET/CT images in malignant and benign thyroid nodules according to nodule
volume
Volume of nodule Pathology Visual analysis of 18F-FDG uptake Number (%) p value
Below 1 cm3 (n = 98) Malignant nodule (n = 82) Uptake 55 (67.1 %) 0.572
No uptake 27 (32.9 %)
Benign nodule (n = 16) Uptake 11 (68.8 %)
No uptake 5 (31.2 %)
Equal to or above 1 cm3 (n = 94) Malignant nodule (n = 70) Uptake 70 (100 %) <0.001
No uptake 0 (0 %)
Benign nodule (n = 24) Uptake 19 (79.2 %)
No uptake 5 (20.8 %)
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and 7.72 ± 3.44 for anaplastic carcinoma. In the benign
cases, it was 2.45 ± 0.27 for nodular hyperplasia and 1.05 ±
1.05 for follicular adenoma.
Differences in 18F-FDG uptake on visual analysis and
SUVmax between malignant and benign nodules
stratified by nodule volume
The differences between malignant and benign nodules in
terms of visual 18F-FDG uptake and SUVmax, stratified by
nodule volume, are shown in Tables 1 and 2. In nodules
smaller than 1 cm3 (98 cases), 18F-FDG uptake on visual
analysis was not different between the malignant and be-
nign cases (p = 0.572). However, in nodules ≥1 cm3 (94
cases), it was significantly higher in malignant than in be-
nign nodules (all patients with malignant nodules vs.
79.2 % of patients with benign nodules; p < 0.001)
(Table 1). In nodules <1 cm3, mean SUVmax was 1.90 ±
0.21 in the malignant cases and 2.15 ± 0.42 in the benign
cases (p = 0.630). However, it was significantly higher in
malignant nodules with volumes ≥1 cm3 (8.88 ± 0.82 for
malignant vs. 2.55 ± 0.33 for benign nodules, p < 0.001)
(Table 2).
Correlation between nodule volume and SUVmax
There was no significant correlation between the volumes
of all thyroid nodules and mean SUVmax (Pearson’s cor-
relation coefficient, r = 0.149). Likewise, there was no sig-
nificant correlation between the volume of malignant
nodules only and mean SUVmax (r = 0.151). When strati-
fied by volume, a weak correlation (r = 0.452) withTable 2 Mean SUVmax of malignant and benign nodules according
Volume of nodule Pathology
Below 1 cm3 (n = 98) Malignant nodule (n
Benign nodule (n = 1
Equal to or above 1 cm3 (n = 94) Malignant nodule (n
Benign nodule (n = 2
SUVmax maximum standardized uptake value of 18F-FDG PET/CTSUVmax was observed in the case of small (<1 cm3) ma-
lignant nodules, but not in the case of larger (≥1 cm3) ma-
lignant nodules (r = 0.076).
Diagnostic accuracy of 18F-FDG PET/CT, US, and FNAC
In the case of volumes ≥1 cm3, a receiver operating
characteristic (ROC) curve analysis determined the opti-
mal value of SUVmax for differential diagnosis between
benign and malignant thyroid nodules (Fig. 1). The diag-
nostic power of 18F-FDG PET/CT was the highest at
SUVmax = 6: at that value, it had 60.8 % sensitivity,
96.8 % specificity, a positive predictive value of 97.7 %, a
negative predictive value of 48.4 %, and 70.2 % diagnos-
tic accuracy.
We compared the results of thyroid US, FNAC, and
18F-FDG PET/CT at that cut-off value. Their respective
sensitivities were 96.4, 99.1, and 60.8 %, and respective
specificities were 95.9, 98.2, and 96.8 %. Similarly, their
respective positive predictive values were 98.9, 99.4, and
97.7 %, and respective negative predictive values were
86.8, 95.2, and 48.4 %. Diagnostic accuracy was 97.3 %
for thyroid US, 98.8 % for FNAC, and 70.2 % for 18F-
FDG PET/CT.
Diagnostic accuracy of 18F-FDG PET/CT in cases
undiagnosed by FNAC
FNAC diagnosed 151 cases of malignancy or suspected
malignancy, 35 benign cases, 4 cases classified as inde-
terminate, and 2 as inadequate. Of the 151 supposed
malignancies, 1 was found to be benign after thyroidec-
tomy. Of the four indeterminate cases, two wereto nodule volume
Mean SUVmax p value
= 82) 1.90 ± 0.21 0.630
6) 2.15 ± 0.42
= 70) 8.88 ± 0.82 <0.001
4) 2.55 ± 0.33
Fig. 1 Receiver operating characteristic (ROC) curve of SUVmax. The
diagnostic power of 18F-FDG PET/CT is the highest at SUVmax = 6
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adenomas (Figs. 2 and 3). The cases classified as inad-
equate were found to be nodular hyperplasia (Table 3).
When the six patients with indeterminate or inad-
equate findings on FNAC were examined by 18F-FDG
PET/CT (with a cut-off SUVmax = 6), the method had
100 % sensitivity and specificity, 0 % false positives and
false negatives, positive and negative predictive values of
100 %, and 100 % diagnostic accuracy.Fig. 2 Images of follicular adenoma. a On ultrasonography, there is an 8-cm
the left lobe on 18F-FDG PET/CT (SUVmax = 2.10)Discussion
In our study, the mean SUVmax was on the whole sig-
nificantly higher in malignant than in benign thyroid
nodules (p < 0.001). However, when the nodules were
stratified by volume, we observed no significant differ-
ences in 18F-FDG uptake on visual analysis and in mean
SUVmax between the malignant and benign nodules
when the nodules were below 1 cm3. This might be due
to the partial-volume effect, i.e., underestimation of
small volumes. The resolution of 18F-FDG PET/CT is es-
timated at approximately 6 mm3 [10]. When 18F-FDG
PET/CT is performed on smaller lesions, the adjacent
normal tissue that does not show increased uptake is
also present in the visual field, and this may lead to in-
accurate assessment of FDG uptake. Hence, in this
study, we evaluated the diagnostic accuracy of 18F-FDG
PET/CT only in nodules with a volume ≥1 cm3 except
for those nodules <1 cm3 in which neither visual analysis
of uptake nor mean SUVmax had any power to differen-
tiate between malignant and benign nodules.
As a tool in the differential diagnosis of benign and
malignant thyroid nodules, thyroid US has been shown
to have sensitivity of 30–75 %, specificity of 80–95 %,
positive predictive value of 15–94 %, negative predictive
value of 70–80 %, and diagnostic accuracy of approxi-
mately 75 % [11, 12]. By comparison, the sensitivity and
specificity of FNAC have been estimated at approxi-
mately 85–90 % and 85–97 %, respectively, although
these values may vary depending on the examiner’s tech-
nical skills [13, 14]. In our study, both thyroid US and
FNAC had a higher diagnostic accuracy than suggested
in the previous reports (the corresponding values for US, markedly hypoechoic nodule. b Mildly increased 18F-FDG uptake in
Fig. 3 Images of follicular carcinoma. a On ultrasonography, there is a 1.7-cm, hypoechoic nodule. b Focal, intense 18F-FDG uptake in the left
isthmic nodule on 18F-FDG PET/CT (SUVmax = 11.97)
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for FNAC: 99.1, 98.2, 99.4, 95.2, and 98.8 %). One of the
contributing factors could be our study criteria, which
excluded patients with negative findings on FNAC des-
pite having intermediate findings or a suspected malig-
nancy on US.
In the current study, the diagnostic ability of 18F-FDG
PET/CT to differentiate benign and malignant thyroid
nodules was lower than that of US or FNAC, even in lar-
ger (≥1 cm3) nodules. This implies that 18F-FDG PET/
CT is less likely to be a primary modality in the differen-
tial diagnosis of all thyroid nodules. Furthermore, the
role of 18F-FDG PET/CT as the primary modality in the
differential diagnosis of thyroid carcinoma may be lim-
ited at the present time because the small thyroid cancer
with a volume of <1 cm3 is common, and the diagnostic
accuracy of 18F-FDG PET/CT is especially low in those
cases. In addition, considering cost-effectiveness, 18F-
FDG PET/CT is not recommended routinely.Table 3 Pathology results and SUVmax on 18F-FDG PET/CT in
cases that were inconclusive on fine needle aspiration cytology
Results of FNAC Group SUVmax Pathology
Indeterminate (n = 4) Malignant (n = 2) 11.97 Follicular carcinoma
8.2 Follicular carcinoma
Benign (n = 2) 2.10 Follicular adenoma
0 Follicular adenoma
Inadequate (n = 2) Benign (n = 2) 2.6 Nodular hyperplasia
0 Nodular hyperplasia
FNAC fine needle aspiration cytology, SUVmax maximum standardized uptake
value of 18F-FDG PET/CTHowever, the SUVmax of 18F-FDG PET/CT might be
useful in the differential diagnosis of thyroid nodule de-
tected incidentally by 18F-FDG PET/CT scan which was
performed for the purpose of routine health examination
or evaluation of metastasis from other malignancy. Our
findings suggest that malignancy can be suspected when
nodules ≥1 cm3 show FDG uptake on visual analysis of
PET/CT images, because all the malignant thyroid nod-
ules with a volume of ≥1 cm3 showed the uptake on vis-
ual analysis. In particular, there is a very high probability
that thyroid nodules with a volume of ≥1 cm3 and SUV-
max of >6 on 18F-FDG PET/CT are thyroid carcinoma
because of a higher specificity of 96.8 % and a positive
predictive value of 97.7 %.
According to reports, differential diagnosis by FNAC
can be difficult in approximately 20 % of thyroid nod-
ules, particularly in the case of non-diagnostic or unsat-
isfactory samples, follicular lesions of undetermined
significance, or follicular neoplasms [15]. The diagnostic
power of 18F-FDG PET/CT in such cases is still contro-
versial [16–19]. Here, we evaluated the role of 18F-FDG
PET/CT in six patients whose preoperative ultrasound-
guided FNAC findings were not conclusively malignant or
benign. In these patients, the sensitivity and specificity of
18F-FDG PET/CT were 100 %, indicating that it might be a
useful modality in cases undiagnosed by FNAC. However,
before these findings can be considered conclusive, they
should be verified in a larger sample of patients.
Inevitably, this study has some limitations. The pa-
tients were not randomized, and there was selection
bias. We included only those who underwent thyroidec-
tomy and 18F-FDG PET/CT for benign or malignant
Kim et al. World Journal of Surgical Oncology  (2015) 13:217 Page 6 of 6nodules. We excluded any benign or indeterminate cases
where thyroidectomy was not indicated and those cases
in which 18F-FDG PET/CT was not performed.
Conclusions
18F-FDG PET/CT is limited as a primary modality in the
differential diagnosis of benign and malignant thyroid
nodules because of its low sensitivity. However, malig-
nancy can be suspected when a visual analysis of 18F-
FDG PET/CT images shows increased FDG uptake in
nodules with volumes ≥1 cm3. In addition, if SUVmax is
greater than 6 in nodules ≥1 cm3, the probability of ma-
lignancy is very high.
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